S-1同步放化疗对比多西他赛联合顺铂治疗局部晚期食管鳞癌
该回顾性研究比较了S-1同步放化疗与多西他赛联合顺铂同步放化疗在局部晚期食管鳞癌患者中的毒性和疗效。共纳入175例患者(S-1组72例,DP组103例),S-1组3-4级不良事件发生率显著更低(22.2% vs. 45.6%,p=0.002),而客观缓解率和3年生存率两组无显著差异。结论认为S-1方案不劣于DP方案,且耐受性更好。
要点
- S-1组3-4级不良事件发生率显著低于DP组(22.2% vs. 45.6%,p=0.002)。
- 两组客观缓解率(68.1% vs. 73.8%,p=0.497)和3年总生存率(34.7% vs. 38.8%,p=0.422)无显著差异。
- DP组中>60岁患者3-4级不良事件发生率显著高于≤60岁患者(58.1% vs. 31.3%,p=0.01)。
核心结论
- S-1同步放化疗不劣于多西他赛联合顺铂同步放化疗,且在老年局部晚期食管鳞癌患者中耐受性更好。
研究设计与样本
- 回顾性研究,纳入2014至2016年间接受同步放化疗的局部晚期食管鳞癌患者175例,S-1组72例,DP组103例。
- S-1组方案:S-1 70 mg/m2 每日两次,第1-14天,每3周重复,共2周期。
- DP组方案:多西他赛25 mg/m2和顺铂25 mg/m2,第1天,每周一次。
- 放疗剂量:1.8-2.0 Gy/次,总剂量50-60 Gy。
主要发现
- S-1组3-4级不良事件发生率为22.2%,DP组为45.6%,差异有统计学意义(p=0.002)。
- DP组中>60岁患者3-4级不良事件发生率为58.1%,≤60岁患者为31.3%,差异有统计学意义(p=0.01)。
- S-1组客观缓解率为68.1%,DP组为73.8%,差异无统计学意义(p=0.497)。
- S-1组3年总生存率为34.7%,DP组为38.8%,差异无统计学意义(p=0.422)。
- DP组3年无进展生存率高于S-1组(33.0% vs. 25.0%),但差异无统计学意义(p=0.275)。
临床怎么用
- 对于局部晚期食管鳞癌患者,S-1同步放化疗可作为多西他赛联合顺铂方案的替代选择,尤其适用于老年患者以降低严重不良事件风险。
局限性
- 本研究为回顾性分析,样本量有限,结论需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This retrospective study was to assess and compare the toxicity and efficacy of concurrent chemoradiotherapy (CCRT) with S-1 or docetaxel and cisplatin in patients with locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: Patients with locally advanced ESCC who received CCRT with S-1 (70 mg/m2 twice daily on days 1-14, every 3 weeks for 2 cycles, S-1 group) or docetaxel (25 mg/m2) and cisplatin (25 mg/m2) on day 1 weekly (DP group) between 2014 and 2016 were retrospectively analyzed. Radiotherapy was delivered in 1.8-2.0 Gy per fraction to a total dose of 50-60 Gy. Treatment-related toxicities (Common Terminology Criteria for Adverse Events version 4.0), response rate, and survival outcomes were compared between groups. RESULTS: A total of 175 patients were included in this study (72 in the S-1 group and 103 in the DP group). Baseline characteristics were well balanced between the two groups. The incidence of grade 3-4 adverse events were significantly lower in the S-1 group than that of the DP group (22.2% vs. 45.6%, p = 0.002). In the DP group, elderly patients (> 60 years) had a significantly higher rate of grade 3-4 adverse events than younger patients (58.1% vs. 31.3%, p = 0.01). The objective overall response rate (complete response + partial response) was 68.1% in the S-1 group, and 73.8% the DP group (p = 0.497). The 3-year overall survival was 34.7% in the S-1 group, and 38.8% in the DP group (p = 0.422). The 3-year progression free survival in the DP group was higher than that in the S-1 group but without significant difference (33.0% vs. 25.0%, p = 0.275). CONCLUSION: CCRT with S-1 is not inferior to CCRT with docetaxel and cisplatin and is better tolerated in in elderly patients with locally advanced ESCC.
引用
- Zhou XL, Yu CH, Wang WW, et al. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2021. PMID: 34039375. doi:10.1186/s13014-021-01821-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。